TRACT Therapeutics
- Company typePrivate
- Founded2013
- HeadquartersChicago, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
TRACT Therapeutics firmographics
Firmographics- Name
- TRACT Therapeutics
- Legal name
- Singulera Therapeutics Inc.
- Website
- https://tracttherapeutics.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
TRACT Therapeutics industry classification
Industry- Product category
- Cell Therapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell Therapy Developers (Autologous) (HLAAABAA)
- akta.pro secondary industries
- Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE), Nephrology & Urology Pharmaceuticals (HLAIAAAM)
Keywords
Where TRACT Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Chicago
- HQ country
- United States
- HQ region
- North America
Markets served
TRACT Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
TRACT Therapeutics product offering
Product offeringCore offering
TRACT Therapeutics (legal name Singulera Therapeutics Inc., previously operating as TRACT Therapeutics) is developing TRK-001, a personalized regulatory T cell therapy platform. The product consists of a patient's own regulatory T cells, which are expanded in a laboratory and given back to the patient as a single dose by infusion with the goal of establishing immune tolerance. The therapy is intended for solid organ transplant patients and patients suffering from an autoimmune disorder, with the potential to reduce or eliminate the need for life-long immunosuppressive drug therapy.
Product overview
Singulera Therapeutics Inc. is developing a single core product, TRK-001, a personalized regulatory T cell therapy platform. The product consists of a patient's own regulatory T cells that are expanded in a laboratory and administered as a single dose by infusion. The therapy targets both solid organ transplant patients and patients with autoimmune disorders, with the goal of establishing immune tolerance and potentially reducing or eliminating the need for lifelong immunosuppressive drug therapy.
Differentiator
Problem solved
Functional benefit
Brands
- TRK-001: A regulatory T cell therapy platform for organ transplant and autoimmune diseases.
Products and services
- TRK-001 TRK-001 is a personalized regulatory T cell therapy platform that uses a patient's own regulatory T cells, expanded in a laboratory and administered as a single-dose infusion to establish immune tolerance. The therapy is intended for solid organ transplant patients and patients suffering from autoimmune disorders, with the goal of preventing transplant rejection while reducing or eliminating the need for life-long immunosuppressive drug therapy.
Quantifiable outcome
- Phase 1 trial demonstrated no safety concerns in kidney transplant patients
- +1 more outcomes
Companies that use TRACT Therapeutics
Customer profileSegments2 records
Ideal customer profiles2 records
TRACT Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
TRACT Therapeutics partnerships and signals
Strategic signalScale indicators4 records
Recent moves6 records
Expansion highlights4 records
TRACT Therapeutics competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
TRACT Therapeutics social profiles
Digital presenceTRACT Therapeutics compliance and trust
Trust signalCompliance1 record
TRACT Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
TRACT Therapeutics leadership team
Management profileNumber of profiles
Profiles2 records
TRACT Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TRACT Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TRACT Therapeutics
What does TRACT Therapeutics do?
TRACT Therapeutics (legal name Singulera Therapeutics Inc., previously operating as TRACT Therapeutics) is developing TRK-001, a personalized regulatory T cell therapy platform. The product consists of a patient's own regulatory T cells, which are expanded in a laboratory and given back to the patient as a single dose by infusion with the goal of establishing immune tolerance. The therapy is intended for solid organ transplant patients and patients suffering from an autoimmune disorder, with the potential to reduce or eliminate the need for life-long immunosuppressive drug therapy.
Is TRACT Therapeutics a public or private company?
TRACT Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was TRACT Therapeutics founded?
TRACT Therapeutics was founded in 2013. It employs 1 to 10 people.
Where is TRACT Therapeutics based?
TRACT Therapeutics is headquartered in Chicago, United States, in the North America region.
Does TRACT Therapeutics have an API?
No public API is recorded for TRACT Therapeutics.
What industry is TRACT Therapeutics in?
TRACT Therapeutics's product category is Cell Therapy. Its primary akta.pro industry code is HLAAABAA, Cell Therapy Developers (Autologous), with a secondary code of HLAIAIAE, Rare Immunology, Autoimmune & Autoinflammatory Therapies. Its NAICS code is 325414 and its SIC code is 2836.